Venous stenting practice

Coordinators:
Ana Isabel Simoes Ferreira, Cormac O'Brien

Participating corporate partners:
Boston Scientific
Medtronic

There are a variety of different similar products for this procedure beyond the ones demonstrated in this session.

CIRSE 2024 – HDT SESSIONS
VENOUS STENTING + IVUS

Boston Scientific

WALLSTENT™ UNI Venous Stent

Clinically proven; Case after case

High durability
Specifically engineered to provide **fracture resistance**.

Braided architecture
Braided design with Elgiloy® material provides **compression resistance** in venous anatomy.

Unique conformability
Designed for optimal **conformability** so it can be deployed effectively in curved / tapered vessels.

Avvigo™+ system & OptiCross™ catheter – IVUS technology

Leveraging confidence



State-of-the-Art Multi-Modality Platform

Best-in-Class IVUS Imaging Catheters

Venous Self-Expanding Stent System

Abre™

The Abre™ Venous Self-Expanding Stent system is designed for the unique challenges of venous disease. It offers easy deployment, to let physicians focus on their patient, and delivers demonstrated endurance, to give patients freedom of movement.[1,2]

The ABRE clinical study

Clinical evidence shows real-world dependability even in challenging cases.[1]

- **81.6%** primary patency at 36 months[1]
- **47.5%** categorized as PTS patients[1]
- **0%** fracture rate in clinical trial[1]
- **44%** of the patients with stents extending below inguinal ligament into the CFV[1]

1Black, M.D., Sapoval, Dexter, et al. Three-Year Outcomes of the Abre Venous Self-Expanding Stent System in Patients With Symptomatic Iliofemoral Venous Outflow Obstruction
2. Test data on file at Medtronic. Report 10558227DOC_Rev A. Bench test results may not be indicative of clinical performance.
* Primary Patency was defined as meeting all of the following criteria at 12 months post-procedure: Freedom from occlusion or restenosis ≥ 50% of the stented segment of the target lesion and freedom from clinically driven target lesion revascularization.
† MAEs included all-cause death, clinically significant pulmonary embolism, procedural major bleeding complication, stent thrombosis, and stent migration. MAEs were adjudicated by a Clinical Events Committee, except stent thrombosis and stent migration, which were assessed by an imaging core laboratory.

Medtronic